Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 1863Lung Neoplasms 1292Small Cell Lung Carcinoma 324Colorectal Neoplasms 273Breast Neoplasms 242Melanoma 221Neoplasms 215Ovarian Neoplasms 192Neoplasm Metastasis 182Pancreatic Neoplasms 155Squamous Cell Carcinoma of Head and Neck 150Stomach Neoplasms 141Head and Neck Neoplasms 121Carcinoma, Renal Cell 119Triple Negative Breast Neoplasms 109Esophageal Neoplasms 108Prostatic Neoplasms 106Endometrial Neoplasms 98Uterine Cervical Neoplasms 96Urinary Bladder Neoplasms 87Colonic Neoplasms 87Mesothelioma 86Mesothelioma, Malignant 80Carcinoma, Hepatocellular 74Brain Neoplasms 70Sarcoma 63Disease 62Adenocarcinoma of Lung 59Carcinoma, Transitional Cell 54Gastrointestinal Neoplasms 50

Interventions

Paclitaxel 2Carboplatin 2pembrolizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Squamous Non-small Cell Lung Cancer × Thoracic × 1 year × Clear all
NCT07221474 2026-05-28

INTerpath-13

Merck Sharp & Dohme LLC

Phase 2 Recruiting
180 enrolled
Thoracic

Squamous Non-small Cell Lung Cancer

NCT07360132 2026-01-22

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Shanghai Huaota Biopharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
480 enrolled
Thoracic

Squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡